

.....
(Original Signature of Member)

116TH CONGRESS
2D SESSION

H. R. _____

To authorize the Patient-Centered Outcomes Research Institute to fund research of the symptoms of COVID-19, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

Mr. BEYER introduced the following bill; which was referred to the Committee
on _____

A BILL

To authorize the Patient-Centered Outcomes Research Institute to fund research of the symptoms of COVID-19, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “COVID-19 Long
5 Haulers Act”.

1 **SEC. 2. AUTHORIZATION TO FUND RESEARCH OF THE**
2 **LONG-TERM SYMPTOMS OF COVID-19 BY THE**
3 **PATIENT-CENTERED OUTCOMES RESEARCH**
4 **INSTITUTE.**

5 (a) IN GENERAL.—The Patient-Centered Outcomes
6 Research Institute under section 1181(b) of the Social Se-
7 curity Act (42 U.S.C. 1320e(b)) shall fund research de-
8 scribed in subsection (b).

9 (b) RESEARCH DESCRIBED.—For purposes of sub-
10 section (a), research described in this subsection shall in-
11 clude—

12 (1) prior to creating a patient registry described
13 in paragraph (2), survey existing patient registries
14 that include individuals experiencing post-acute
15 sequelae of COVID-19;

16 (2) creating a patient registry for those with
17 COVID-19 with information that—

18 (A) contains the—

19 (i) symptoms that arise while an indi-
20 vidual is actively infected with COVID-19
21 and that resolve while such individual is
22 actively infected;

23 (ii) symptoms that arise while an indi-
24 vidual is actively infected with COVID-19
25 and that extend after the infection has re-
26 solved;

1 (iii) symptoms that arise after an in-
2 dividual is actively infected with COVID-
3 19 and that endure and that the clinician
4 of such individual has reason to suspect
5 were related to the COVID-19 diagnosis;

6 (iv) symptoms that arise in an indi-
7 vidual that may be related to COVID-19
8 but a diagnosis of COVID-19 was not ob-
9 tained and cannot be identified due to a
10 lack of antibodies;

11 (v) treatments of individuals after pri-
12 mary diagnosis to COVID-19 and the ef-
13 fectiveness of such treatments
14 disaggregated by age, gender, and race or
15 ethnicity; and

16 (vi) any other relevant questions or
17 issues related to individuals who experience
18 a diagnosis of, treatment for, and manage-
19 ment of care with COVID-19;

20 (B) synthesizes information relating to in-
21 dividuals experiencing post-acute sequelae of
22 COVID-19 identified from the survey described
23 in paragraph (1) and information under the pa-
24 tient registry described in paragraph (2); and

